



## IND and IMPD-Enabling Packages

Pharmaron is able to support the preclinical and CMC development demands for a new drug candidate to be IND-ready or IMPD-ready for First-in-Human (FIH) clinical trials. Pharmaron's global team of cell and gene therapy drug developers are experienced with authoring regulatory dossiers and interacting with regulators during scientific advice or pre-IND meetings.

### Preclinical Testing

- Proof of concept to GLP toxicology studies
- Broad range of disease models in different species with expertise across all routes of administration
- Access to board-certified toxicologists and veterinarians
- Comprehensive suite of bioanalytical assays (NAb, ADA, ELISPOT, biodistribution, shedding, biomarkers)
- Product-based testing strategy with a comprehensive set of analytical platforms

### Services

#### Chemistry, Manufacturing and Control

- **Manufacture of drug substance for preclinical, and toxicology studies; manufacture of plasmids** (research and GMP Grade)
- **Analytical and potency assay method development, qualification/validation** to support release of drug product for FIH
- **Stability testing** and shelf-life assignment
- **Manufacture & QC release testing of drug substance and drug product** for clinical studies

#### Pharmacology/Toxicity

- **Preclinical study design, data acquisition, interpretation, bioanalytical** method development and validation (GLP, Non-GLP)

#### Regulatory

- **Authoring preclinical, CMC sections** for IND and/or IMPD submission dossiers

### CMC Development

- 80,000 ft<sup>2</sup> state-of-the-art development and GMP manufacturing
- MHRA approved GMP facility
- Animal-free, scalable platform manufacturing process from 15mL to 500L
- Suspension culture and chromatography-based purification
- High throughput process development
- Platform suite of analytics
- Production of critical starting materials (cell banks & plasmids)

